NCT05401565 - Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

October 5, 2023

Study Completion Date

October 5, 2023

Conditions

Stress Disorders, Post-Traumatic

Interventions

DRUG

Balovaptan

Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period

DRUG

Placebo

Matching placebo

Trial Locations (15)

10016

Bioscience Research, LLC, New York

29464

Coastal Carolina Research Center, Mt. Pleasant

32607

Sarkis Clinical Trials, Gainesville

33016

Galiz Research, LLC, Hialeah

33173

Florida International Research Center, Miami

48105

Michigan Clinical Research Institute PC - Clinedge - PPDS, Ann Arbor

55417

Va Medical Center, Minneapolis

60523

American Medical Research, Inc, Oak Brook

68526

Alivation Research, LLC, Lincoln

78737

Donald J. Garcia Jr., MD, PA, Austin

85012

Alea Research, Phoenix

90706

CITrials, Inc., Bellflower

91402

ASCLEPES Research Centers, Panorama City

92705

Clinical Innovations, Inc, Santa Ana

02135

Boston Clinical Trials & Medical Research, Roslindale

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY